Celldex Therapeutics
Clinical trials sponsored by Celldex Therapeutics, explained in plain language.
Biotech developing immunotherapies for cancer and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New hope for chronic hive sufferers: drug shows promise in major trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New asthma drug enters early human safety testing Results expected Mar 2027 (estimated)
-
New shot may stop hives from cold and scratching
Disease control Recruiting nowThis study tests an investigational drug called barzolvolimab in 240 adults who get hives from cold temperatures or from scratching their skin, and whose symptoms are not controlled by standard allergy pills. Participants receive either the drug or a placebo injection, and doctor…
Phase 3 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New asthma drug enters early human safety testing
Symptom relief Recruiting nowThis early-stage study tests a single dose of an experimental drug called CDX-622 in 12 adults with mild to moderate asthma. The main goal is to see if the drug is safe and to measure how it affects markers of airway inflammation. Participants will be monitored for side effects a…
Phase 1 • Sponsor: Celldex Therapeutics • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC